Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

NCT06083129 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

324

Enrollment

OTHER

Sponsor class

Conditions

GVHD

Interventions

DRUG: Grafalon
DRUG: Thymoglobulin

Sponsor

Assistance Publique - Hôpitaux de Paris